Literature DB >> 26260437

Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits.

Norbert Schuff1,2, I-Wei Wu1,2, Shannon Buckley1,2, Eric D Foster3, Christopher S Coffey3, Darren R Gitelman4, Susan Mendick5, John Seibyl5, Tanya Simuni4, Yu Zhang1,2, Joseph Jankovic6, Christine Hunter6, Caroline M Tanner1,7, Linda Rees7, Stewart Factor8, Daniela Berg9, Isabel Wurster9, Katharina Gauss9, Fabienne Sprenger10, Klaus Seppi10, Werner Poewe10, Brit Mollenhauer11, Susanne Knake11, Zoltan Mari12, Arita McCoy12, Madelaine Ranola13, Kenneth Marek5.   

Abstract

BACKGROUND: This study reports the baseline characteristics of diffusion tensor imaging data in Parkinson's disease (PD) patients and healthy control subjects from the Parkinson's Progression Markers Initiative. The main goals were to replicate previous findings of abnormal diffusion imaging values from the substantia nigra. in a large multicenter cohort and determine whether nigral diffusion alterations are associated with dopamine deficits.
METHODS: Two hundred twenty subjects (PD = 153; control = 67) from 10 imaging sites were included. All subjects had a full neurological exam, a ((123) I)ioflupane dopamine transporter (DAT) single-photon emission computer tomography scan, and diffusion tensor imaging. Fractional anisotropy as well as radial and axial diffusivity was computed within multiple regions across the substantia nigra.
RESULTS: A repeated-measures analysis of variance found a marginally nonsignificant interaction between regional fractional anisotropy of the substantia nigra and disease status (P = 0.08), conflicting with an earlier study. However, a linear mixed model that included control regions in addition to the nigral regions revealed a significant interaction between regions and disease status (P = 0.002), implying a characteristic distribution of reduced fractional anisotropy across the substantia nigra in PD. Reduced fractional anisotropy in PD was also associated with diminished DAT binding ratios. Both axial and radial diffusivity were also abnormal in PD.
CONCLUSIONS: Although routine nigral measurements of fractional anisotropy are clinically not helpful, the findings in this study suggest that more-sophisticated diffusion imaging protocols should be used when exploring the clinical utility of this imaging modality.
© 2015 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  dopamine; fractional anisotropy; neuroimaging; substantia nigra

Mesh:

Substances:

Year:  2015        PMID: 26260437     DOI: 10.1002/mds.26325

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  29 in total

1.  Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study.

Authors:  Edward Ofori; Florian Krismer; Roxana G Burciu; Ofer Pasternak; Johanna L McCracken; Mechelle M Lewis; Guangwei Du; Nikolaus R McFarland; Michael S Okun; Werner Poewe; Christoph Mueller; Elke R Gizewski; Michael Schocke; Christian Kremser; Hong Li; Xuemei Huang; Klaus Seppi; David E Vaillancourt
Journal:  Mov Disord       Date:  2017-07-17       Impact factor: 10.338

2.  Multimodal dopaminergic and free-water imaging in Parkinson's disease.

Authors:  Jing Yang; Derek B Archer; Roxana G Burciu; Martijn L T M Müller; Arnab Roy; Edward Ofori; Nicolaas I Bohnen; Roger L Albin; David E Vaillancourt
Journal:  Parkinsonism Relat Disord       Date:  2019-01-06       Impact factor: 4.891

Review 3.  Substantia nigra fractional anisotropy is not a diagnostic biomarker of Parkinson's disease: A diagnostic performance study and meta-analysis.

Authors:  Fabiana C C Hirata; João R Sato; Gilson Vieira; Leandro T Lucato; Claudia C Leite; Edson Bor-Seng-Shu; Bruno F Pastorello; Maria C G Otaduy; Khallil T Chaim; Kenia R Campanholo; Natalia P Novaes; Luciano Magalhães Melo; Márcia R Gonçalves; Felipe Barjud Pereira do Nascimento; Manoel Jacobsen Teixeira; Egberto Reis Barbosa; Edson Amaro; Ellison Fernando Cardoso
Journal:  Eur Radiol       Date:  2016-10-05       Impact factor: 5.315

4.  Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease.

Authors:  Yu Zhang; I-Wei Wu; Shannon Buckley; Christopher S Coffey; Eric Foster; Susan Mendick; John Seibyl; Norbert Schuff
Journal:  Mov Disord       Date:  2015-04-29       Impact factor: 10.338

5.  High-Spatial-Resolution Diffusion MRI in Parkinson Disease: Lateral Asymmetry of the Substantia Nigra.

Authors:  Zheng Zhong; Douglas Merkitch; M Muge Karaman; Jiaxuan Zhang; Yi Sui; Jennifer G Goldman; Xiaohong Joe Zhou
Journal:  Radiology       Date:  2019-02-19       Impact factor: 11.105

Review 6.  Magnetic resonance imaging for the diagnosis of Parkinson's disease.

Authors:  Beatrice Heim; Florian Krismer; Roberto De Marzi; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2017-04-04       Impact factor: 3.575

7.  Free-water imaging in Parkinson's disease and atypical parkinsonism.

Authors:  Peggy J Planetta; Edward Ofori; Ofer Pasternak; Roxana G Burciu; Priyank Shukla; Jesse C DeSimone; Michael S Okun; Nikolaus R McFarland; David E Vaillancourt
Journal:  Brain       Date:  2015-12-24       Impact factor: 13.501

8.  Substantia Nigra Free Water Increases Longitudinally in Parkinson Disease.

Authors:  T Guttuso; N Bergsland; J Hagemeier; D G Lichter; O Pasternak; R Zivadinov
Journal:  AJNR Am J Neuroradiol       Date:  2018-02-01       Impact factor: 3.825

9.  White matter abnormalities in the corpus callosum with cognitive impairment in Parkinson disease.

Authors:  Ian O Bledsoe; Glenn T Stebbins; Doug Merkitch; Jennifer G Goldman
Journal:  Neurology       Date:  2018-11-14       Impact factor: 9.910

10.  Dopaminergic Nigrostriatal Connectivity in Early Parkinson Disease: In Vivo Neuroimaging Study of 11C-DTBZ PET Combined with Correlational Tractography.

Authors:  Carlos A Sanchez-Catasus; Nicolaas I Bohnen; Fang-Cheng Yeh; Nicholas D'Cruz; Prabesh Kanel; Martijn L T M Müller
Journal:  J Nucl Med       Date:  2020-08-28       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.